Literature DB >> 19229709

Health status and the spiral of decline.

Paul W Jones1.   

Abstract

COPD is complex and there are multiple determinants of poor health, so most studies of Chronic Obstructive Pulmonary Disease (COPD) now include health status, or health related quality of life measurement, along with FEV(1) as a primary endpoint. It is important to make a distinction between quality of life-which is unique to the individual, and health status measurement-which is standardized quantification of the impact of disease. Health status scores correlate weakly with FEV(1) but they are predictors of mortality independently of age and FEV(1). The determinants of impaired health status may change over time and the clinical consequences associated with a given change in score may change with disease progression. The largest study to date suggests that health status decline is linear over time, but longer-term studies are needed to confirm these findings. Inhaled corticosteroids have been shown to reduce the rate of decline of health status, possibly due to exacerbation prevention.

Entities:  

Mesh:

Year:  2009        PMID: 19229709     DOI: 10.1080/15412550802587943

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  53 in total

Review 1.  Biomarkers in airway diseases.

Authors:  Janice M Leung; Don D Sin
Journal:  Can Respir J       Date:  2013 May-Jun       Impact factor: 2.409

2.  Racial differences in quality of life in patients with COPD.

Authors:  MeiLan K Han; Douglas Curran-Everett; Mark T Dransfield; Gerard J Criner; Lening Zhang; James R Murphy; Nadia N Hansel; Dawn L DeMeo; Nicola A Hanania; Elizabeth A Regan; Barry J Make; Fernando J Martinez; Gloria E Westney; Marilyn G Foreman
Journal:  Chest       Date:  2011-06-02       Impact factor: 9.410

3.  Factors associated with the quality of life of Korean COPD patients as measured by the EQ-5D.

Authors:  Ji Young Hong; Song Yee Kim; Kyung Soo Chung; Eun Young Kim; Ji Ye Jung; Moo Suk Park; Young Ae Kang; Se Kyu Kim; Joon Chang; Young Sam Kim
Journal:  Qual Life Res       Date:  2015-04-05       Impact factor: 4.147

Review 4.  Systematic Review of the Association Between Laboratory- and Field-Based Exercise Tests and Lung Function in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Martin Bell; Iain Fotheringham; Yogesh Suresh Punekar; John H Riley; Sarah Cockle; Sally J Singh
Journal:  Chronic Obstr Pulm Dis       Date:  2015-07-08

5.  Effects of GOLD-Adherent Prescribing on COPD Symptom Burden, Exacerbations, and Health Care Utilization in a Real-World Setting.

Authors:  David M Mannino; Tzy-Chyi Yu; Huanxue Zhou; Keiko Higuchi
Journal:  Chronic Obstr Pulm Dis       Date:  2015-06-19

6.  Dynamic-Ventilatory Digital Radiography in Air Flow Limitation: A Change in Lung Area Reflects Air Trapping.

Authors:  Noriyuki Ohkura; Kazuo Kasahara; Satoshi Watanabe; Johsuke Hara; Miki Abo; Takashi Sone; Hideharu Kimura; Munehisa Takata; Masaya Tamura; Isao Matsumoto; Yusuke Nakade; Shigeru Sanada; Rie Tanaka
Journal:  Respiration       Date:  2020-04-29       Impact factor: 3.580

7.  Diffusing Capacity of Carbon Monoxide in Assessment of COPD.

Authors:  Aparna Balasubramanian; Neil R MacIntyre; Robert J Henderson; Robert L Jensen; Gregory Kinney; William W Stringer; Craig P Hersh; Russell P Bowler; Richard Casaburi; MeiLan K Han; Janos Porszasz; R Graham Barr; Barry J Make; Robert A Wise; Meredith C McCormack
Journal:  Chest       Date:  2019-07-25       Impact factor: 9.410

Review 8.  Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.

Authors:  K Suresh Babu; Jack A Kastelik; Jaymin B Morjaria
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

Review 9.  Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations.

Authors:  Thomas Glaab; Claus Vogelmeier; Roland Buhl
Journal:  Respir Res       Date:  2010-06-17

Review 10.  [Chronic obstructive pulmonary disease (COPD). Current concepts and new therapeutic options].

Authors:  A Klemmer; T Greulich; A R Koczulla; C F Vogelmeier
Journal:  Internist (Berl)       Date:  2014-04       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.